Pyrazolo[1,5-a]pyridine derivatives, preparation method therefor and use thereof
A pyrazolo[1,5-a]pyridine derivative, and a preparation method and medical use thereof are provided. The pyrazolo[1,5-a]pyridine derivative shown in general formula (I), a preparation method of the derivative, a pharmaceutically acceptable salt of the derivative, and use of the derivative or salt as a therapeutic agent, especially as a rearranged during transfection (RET) inhibitor, are provided.
1 . A compound, represented by general formula (I):
wherein the ring A is
X 1 and X 2 are each independently selected from the group consisting of CH, CCH 3 , CF, CCl, and N;
X 3 and X 4 are each independently selected from the group consisting of CH, CF, and N;
0, 1, or 2 of X 1 , X 2 , X 3 , and X 4 is/are N;
L 1 is selected from the group consisting of a bond, —(R a R b C)—, —(R a R b N)—, and —O—;
L 2 is selected from the group consisting of a bond, -(alkylene)-, —C(O)—, —S(O)—, —SO 2 —, -(alkylene)-O—, -(alkylene)-S—, -(alkylene)-NR 1 —, —C(O)-(alkylene)-, and —SO 2 -(alkylene)-, and the alkylene is optionally substituted by one or more substituents selected from the group consisting of hydroxyl, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 2 R 3 , —C(O)NR 2 R 3 , —C(O)R 4 , —OC(O)R 4 , —NR 2 C(O)R 3 , and —SO 2 NR 2 R 3 ;
R a is selected from the group consisting of hydrogen, alkyl, and halogen;
R b is selected from the group consisting of hydrogen, alkyl, and halogen;
or, R a and R b , together with C or N atoms attached thereto, form 3-6 membered cycloalkyl or heterocyclyl, wherein the heterocyclyl comprises one or more N, O, and S(O) n atoms, and the cycloalkyl or the heterocyclyl is optionally substituted by one or more substituents selected from the group consisting of hydroxyl, halogen, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 2 R 3 , —C(O)NR 2 R 3 , —C(O)R 4 , —OC(O)R 4 , —NR 2 C(O)R 3 , and —SO 2 NR 2 R 3 ;
B is selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted by one or more substituents selected from Re;
E is selected from the group consisting of hydrogen, alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein the cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted by one or more substituents selected from the group consisting of hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 2 R 3 , —C(O)NR 2 R 3 , —C(O)R 4 , —OC(O)R 4 , —NR 2 C(O)R 3 , and —SO 2 NR 2 R 3 ;
R c is selected from the group consisting of hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 2 R 3 , —C(O)NR 2 R 3 , —C(O)R 4 , —OC(O)R 4 , —NR 2 C(O)R 3 , and —S(O) 2 NR 2 R 3 , wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted by one or more substituents selected from the group consisting of hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 5 R 6 , —C(O)NR 5 R 6 , —C(O)R 7 , —OC(O)R 7 , —NR 5 C(O)R 6 , and —SO 2 NR 5 R 6 ,
R 1 groups are the same or different and are each independently selected from the group consisting of hydrogen, hydroxyl, alkyl, halogen, and alkoxy, wherein the alkyl or alkoxy is optionally substituted by one or more substituents selected from the group consisting of hydroxyl, halogen, and alkoxy;
R 2 , R 3 , and R 4 are each independently selected from the group consisting of hydrogen, hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted by one or more substituents selected from the group consisting of hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, —NR 5 R 6 , —C(O)NR 5 R 6 , —C(O)R 7 , —OC(O)) R 7 , —NR 5 C(O)R 6 , and —SO: NR 5 R 6 ;
or, R 2 and R 3 , together with N atoms attached thereto, form 4-8 membered heterocyclyl, wherein the 4-8 membered heterocyclyl comprises one or more N, O, S(O) n atoms, and the 4-8 membered heterocyclyl is optionally substituted by one or more substituents selected from the group consisting of hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, ═O, —NR 5 R 6 , —C(O)NR 5 R 6 , —C(O)R 7 , —OC(O)) R 7 , —NR 5 C(O)R 6 , and —SO 2 NR 5 R 6 ;
R 5 , Re and R 7 are each independently selected from the group consisting of hydrogen, alkyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl, wherein the alkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted by one or more substituents selected from the group consisting of hydroxyl, halogen, nitro, cyano, alkyl, alkoxy, cycloalkyl, heterocyclyl, aryl, heteroaryl, carboxyl, and carboxylate;
m is selected from the group consisting of 0, 1, 2, 3, 4, and 5;
n is selected from the group consisting of 0, 1, and 2.
2 . The compound according to claim 1 , which is a compound of general formula (II):
wherein
L 1 is —O—;
L 2 , B, E, X 1 , X 2 , X 3 , X 4 , R 1 , R a , R b , and m are as defined in claim 1 .
3 . The compound according to claim 1 , wherein
X 1 , X 2 , X 3 , and X 4 are each selected from the group consisting of CH and N;
0, 1, or 2 of X 1 , X 2 , X 3 , and X 4 is/are N; and
X 1 is N, and X 2 , X 3 , and X 4 are CH.
4 . The compound according to claim 1 , wherein
L 2 is selected from the group consisting of a bond, -(alkylene)-, —C(O)—, —SO 2 —, -(alkylene)-O—, -(alkylene)-S—, -(alkylene)-NR 1 —, and —C(O)-(alkylene)-.
5 . The compound according to claim 1 , wherein B is selected from the group consisting of:
(i) 5-6 membered heteroaryl, wherein the heteroaryl is optionally substituted by one or more substituents selected from the group consisting of alkyl and halogen;
(ii) alkyl, wherein the alkyl is optionally substituted by one or more hydroxyl;
(iii) alkenyl or alkynyl, wherein the alkenyl or alkynyl is optionally substituted by one or more hydroxyl.
6 . The compound according to claim 1 , wherein the compound is selected from the group consisting of:
7 . The compound according to claim 2 , wherein
X 1 , X 2 , X 3 , and X 4 are each selected from the group consisting of CH and N;
0, 1, or 2 of X 1 , X 2 , X 3 , and X 4 is/are N; and
X 1 is N, and X 2 , X 3 , and X 4 are CH.
8 . The compound according to claim 2 , wherein
L 2 is selected from the group consisting of a bond, -(alkylene)-, —C(O)—, —SO 2 —, -(alkylene)-O—, -(alkylene)-S—, -(alkylene)-NR 1 —, and —C(O)-(alkylene)-.
9 . The compound according to claim 2 , wherein B is selected from the group consisting of:
(i) 5-6 membered heteroaryl, wherein the heteroaryl is optionally substituted by one or more substituents selected from the group consisting of alkyl and halogen;
(ii) alkyl, wherein the alkyl is optionally substituted by one or more hydroxyl;
(iii) alkenyl or alkynyl, wherein the alkenyl or alkynyl is optionally substituted by one or more hydroxyl.
10 . A pharmaceutical composition comprising an effective amount of the compound according to claim 1 , and a pharmaceutically acceptable carrier or an excipient.
11 . A preparation method of the compound according to claim 1 , comprising:
subjecting a compound of a general formula (IA) to a reaction with E-(alkylene)-OMs, EC(O)X, E-(alkylene)-C(O)X, or E-C(O)H to obtain the compound of the general formula (I),
wherein X is selected from the group consisting of hydroxyl and halogen, and the halogen comprises Cl, and Br;
L 1 , L 2 , B, E, X 1 , X 2 , X 3 , X 4 , R 1 , and m are as defined in claim 1 .
12 . A compound, represented by general formula (IA):
wherein L 1 , B, X 1 , X 2 , X 3 , X 4 , R 1 , and m are as defined in claim 1 .
13 . The compound according to claim 12 , wherein the compound is selected from the group consisting of: